Flavio Vincenti
Internal Medicine · San Francisco, CANPI 1790732543
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Merck at 38.2% of the total. 2025 is the largest year on record at $74,253, 7.1 times the $10,394 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 115 payments — averaging $1588.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$70K
- Takeda Pharmaceuticals U.S.A., Inc.$26K
- AstraZeneca$23K
- Sanofi-aventis U.S. LLC$13K
- Sanofi$10K
- Mallinckrodt Hospital Products Inc.$9K
- plus $32K from 8 others
Across 530 payments — averaging $5054.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$726K
- Regeneron$600K
- Amgen$469K
- Sanofi US Services Inc.$369K
- CSL Behring$182K
- E.r. Squibb & Sons, L.L.C.$70K
- plus $263K from 7 others
What the payments were for
- Consulting fees$107,09959%
- Speaking & faculty fees$20,55311%
- Travel & lodging$49,33727%
- Food & beverage$2,1411%
- Education$3,5252%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 54 | $69,856 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $26,381 |
| AstraZeneca | 13 | $22,981 |
| Sanofi-aventis U.S. LLC | 2 | $12,527 |
| Sanofi | 7 | $9,802 |
| Mallinckrodt Hospital Products Inc. | 5 | $8,823 |
| E.r. Squibb & Sons, L.L.C. | 12 | $8,204 |
| Veloxis Pharmaceuticals, Inc. | 4 | $7,775 |
| Sanofi US Services Inc. | 3 | $7,151 |
| CSL Behring | 1 | $3,464 |
| Genentech, Inc. | 1 | $2,925 |
| Calliditas Therapeutics US Inc. | 1 | $2,155 |
| Novartis | 1 | $443 |
| Amgen(2 entities) | 3 | $168 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GAMMAGARD LIQUID$25,149
- PREVYMIS$23,583
- THYMOGLOBULIN$9,592
- Envarsus$7,909
- UVADEX$6,750
- ULTOMIRIS$6,601
- NULOJIX$3,525
- TARPEYO$2,155
- CELLEX$2,073
- KRYSTEXXA$104
How this compares
$182,655 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in San Francisco
- Fred CohenSan Francisco$929K
- John TeerlinkSan Francisco$819K
- Mark SmithSan Francisco$535K
- Lisa CapaldiniSan Francisco$434K
- Maria Dall'eraSan Francisco$417K
- Kenneth ColleySan Francisco$397K
- Louis CubbaSan Francisco$351K
- Daniel ButlerSan Francisco$347K
- Laurence CorashSan Francisco$336K
- Felicia StermanSan Francisco$298K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.